Practical Fragments

It’s been a while since our last “getting misled by crystal structures” post . That one described unrecognized conformational heterogeneity ...

Earlier this year I wrote about archiving crystallographic fragment data, and indeed a meeting is planned for early next year to establish ...

Halogen bonds (or X-bonds) are one of the less appreciated protein-ligand interactions. As we discussed in 2022, the polarized nature of a ...

Three years ago we highlighted a growing debate about how and where to house crystallographic fragment data. With the recent surge in high-...

I love this blog.  But sometimes it drags.  Finding new articles to blog about can be hard, there seems to be waves.  So, I love it when so...

So, what I know about the details of crystallography can fit on the head of a pin...a small pin.  You put pure protein in multiwell plates ...

So, not everybody agrees with me on what a fragment is .  As has been pointed out years ago, FBDD can be a FADD .  In this paper , from ea...

As the readers of this blog know, I tend to be harsh on academic "Drug discovery" papers.  Sometimes, there is a really worthwhil...

The year is coming to an end, and as we did last year , Practical Fragments is looking back at notable events as well as reviews that we h...

Protein-protein interactions have often been targeted by fragment efforts, partly I think out of desperation when all else fails. That said...

Checkpoint Kinase 2 (CHK2) is an oncology target that has been kicking around for years. Its relevance is still debated, so having more sma...

Protein-protein interactions (PPIs) are some of the tougher targets in drug discovery: they often have relatively flat interfaces that lack...

The last major fragment event of 2013, CHI’s FBDD , wrapped up earlier this week in San Diego. As with last year this summary is not meant...

CHI’s annual FBDD meeting took place in San Diego this week, and since this was the first time in a while both Teddy and I have been in ...

Zenobia Therapeutics hosted a one-day FBLD meeting in San Diego last Friday. It was a very full day of seven talks and plenty of informal ...

One of the key advantages of fragment-based drug discovery is that, since there are fewer fragments than lead-sized or drug-sized molecules,...

The only US-based conference completely devoted to fragment-based drug discovery ended in San Diego this week. As with last year , I won’t ...